Course and complications of varicella zoster ophthalmicus in a high HIV seroprevalence population (Cape Town, South Africa).
OBJECTIVE
To describe the course and complications of varicella zoster ophthalmicus (VZO) in patients attending an eye clinic in a community with a high HIV seroprevalence.


METHODS
Prospective cohort study of consecutive patients presenting to a tertiary hospital eye clinic with VZO.


METHODS
Patients recruited in 2001 and 2002 received standardized initial topical and systemic management, which was then modified according to complications. Information on the course and complications of the disease was entered in a database prior to statistical analysis.


RESULTS
Information on 102 patients who had 250 visits to the eye clinic was collected. HIV serology was positive, negative, and unknown in 66, 22, and 14 patients, respectively. The most common complication was uveitis (40/102). Median delay from onset of rash to starting acyclovir was 5 days. Complications were present in 33 patients at the first visit. Complications were commoner in patients with positive Hutchinson's sign and were less common at CD4 counts <200. At CD4 counts, > or =200 HIV infection had little effect on the course and complications of VZO. Timing of commencement of Acyclovir therapy within or after 72 h had no demonstrable effect on the incidence of new complications.


CONCLUSIONS
In a resource-limited setting, patients with the following characteristics should have immediate ophthalmic assessment: symptoms suggesting ocular complications or the presence of Hutchinson's sign. All VZO patients should receive antiviral therapy at the first doctor's visit even if they present >72 h after onset of the rash.
Richards
J C
JC
Department of Surgery, University of Cape Town, South Africa. diastella@iinet.net.au
Maartens
G
G
Davidse
A J
AJ
D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D003320:Corneal Ulcer / Q000150:complications; D004334:Drug Administration Schedule; D005260:Female; D015528:HIV Seroprevalence; D006563:Herpes Zoster Ophthalmicus / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013019:South Africa / Q000453:epidemiology; D014605:Uveitis / Q000150:complications
D000998:Antiviral Agents; D000212:Acyclovir